ArticleCornea2026
Survey of Topical Steroid Usage Patterns After Descemet Membrane Endothelial Keratoplasty.
Article in Cornea, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate global practice patterns of topical steroid treatment after Descemet Membrane Endothelial Keratoplasty (DMEK).
methodsAn anonymized electronic questionnaire was disseminated to KeraNet members in March 2024, exploring postoperative corticosteroid use in three scenarios: 1) post-DMEK for Fuchs endothelial corneal dystrophy (FECD), 2) post-DMEK for pseudophakic bullous keratopathy (PBK), and 3) postrepeat DMEK after previous graft failure.
resultsSeventy-eight responses were obtained from ophthalmologists in 15 countries. Participants performed a median of 37.5 DMEKs per year (mean 45.8; SD 46.7; range 2-300). Prednisolone 1% was the preferred topical steroid during the 12 months post-DMEK for FECD, in the 24 months post-DMEK for PBK, and after 24 months postrepeat grafts. Thirty-four surgeons (44%) discontinued topical steroids at 24 months post-DMEK for FECD, whereas 41 (53%) continued steroid drops indefinitely. For PBK, 36% of surgeons ceased topical steroid use at 24 months; 54% continued indefinitely. In repeat DMEKs after previous graft failure, 63% reported indefinite topical steroid treatment. Variability was also noted in long-term follow-up regimens: 45% of surgeons discharge their patients between postoperative years 1 to 5. The remaining 55% of respondents opted for indefinite patient follow-up.
conclusionsWe identified significant variation in postoperative corticosteroid therapy after DMEK for FECD, PBK, and postgraft failure. This heterogeneity warrants further investigations exploring rates of graft rejection and failure across different postoperative steroid regimens. An international consensus would aid in standardizing postoperative care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.